EPFL scientists have now discovered that a DNA-sensing mechanism of the innate immune system - which is pivotal for the immediate defense against pathogens -- controls cellular senescence. The work is ...

The innate immune response constitutes the body’s first line of defence against pathogens, utilising a network of pattern recognition receptors (PRRs) and signalling molecules to detect and neutralise ...

Group 2 innate lymphoid cells (ILC2s) of the immune system are involved in allergic diseases. But currently, therapy targeting ILC2s is not available. Now, researchers have identified a novel ...

Scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings in a study published Sept. 21, 2023, on convergent evolutionary ...

The hydrolysis of endosomal PI(4,5)P2 in the intestine of C. elegans is mediated by RAB-10, a mechanism vital for the establishment of immunity against pathogens. Endosomes manage key metabolic ...

Scientists discover how innate immunity envelops bacteria. The protein GBP1 is a vital component of our body's natural defense against pathogens. This substance fights against bacteria and parasites ...

A section of Goodsell et al.’s magnificent “Integrative illustration for coronavirus outreach” highlighting the packaging of the viral genetic material (in pink) by the scaffold “nucleocapsid protein” ...

Type 1 diabetes (T1D) is an autoimmune disease characterized by the immune-mediated destruction of pancreatic B cells. While autoreactive T cells are key ...

Monash University researchers have discovered a key mechanism in the body's immune system that helps control the inflammatory response to infection. The discovery could help pave the way for more ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

Kupando has raised an additional €10M in Series A financing, bringing its total to €23M, to fund Phase 1b trials of KUP101.